Totality of Evidence



OTULFI® (ustekinumab-aauz)
demonstrated similar efficacy and safety to Stelara® (ustekinumab)1
 

Efficacy in psoriasis
 

Primary Endpoint

Percentage improvement in PASI score from baseline to Week 121
Chart showing improvement in PASI score for OTULFI and Stelara
Chart showing improvement in PASI score for OTULFI and Stelara

*Fully contained within the predefined (−10%; 10%) equivalence margins.

 

Safety in psoriasis

The percentage of patients experiencing adverse events was similar for OTULFI and Stelara1


The Phase 3 study design included a switching arm1

A randomized, double-blind, parallel-group, Phase 3 study of OTULFI® (ustekinumab-aauz) compared with Stelara® (ustekinumab) in patients with moderate to severe plaque psoriasis (N=392)

Study design diagram comparing OTULFI with Stelara for moderate to severe plaque psoriasis
Study design diagram comparing OTULFI with Stelara for moderate to severe plaque psoriasis
  • The initial dose for both products was ​45 mg via pre-filled syringe followed by 45 mg at Week 4 and then 45 mg every ​12 weeks​
  • Patients with PASI improvement of ≥75% at Week 28 were eligible for study continuation
  • Key inclusion criteria: age ≥18 years; PASI score ≥12; PGA score ≥3; body weight ≤100 kg; eligible for systemic therapy or phototherapy
PASI, Psoriasis Area and Severity Index; PFS, pre-filled syringe; PGA, Physician Global Assessment.
 

Efficacy, safety, and immunogenicity were maintained over 1 year1

This included patients who switched from Stelara® (ustekinumab) to OTULFI® (ustekinumab-aauz)1†

Efficacy in psoriasis1
Chart showing efficacy in psoriasis for OTULFI and Stelara
Chart showing efficacy in psoriasis for OTULFI and Stelara

 

89/195 patients switched from Stelara to OTULFI at Week 29.

PASI 75 indicates a 75% or greater reduction in PASI score from baseline, which reflects excellent disease improvement.2

 

Safety in psoriasis1
Percentage of patients who experienced adverse events†,‡


89/195 patients switched from Stelara to OTULFI at Week 29.
No deaths occurred in either group in the study.

 

OTULFI® (ustekinumab-aauz) demonstrated similar NAb and ADA rates over 1 year compared to Stelara® (ustekinumab)3
Percentages of ADA- and NAb-positive patients (RRAS)§
Graph showing similar ADA/NAb rates between OTULFI and Stelara
Graph showing similar ADA and NAb rates between OTULFI and Stelara


§
ADA and NAb rates for OTULFI were numerically lower, but there are no clinically meaningful differences in immunogenicity.

No new ADA-positive patients were identified following the switch from Stelara to OTULFI.

 

ADA, anti-drug antibody; AE, adverse event; CI, confidence interval; LS, least squares; NAb, neutralizing antibody; PASI, Psoriasis Area and Severity Index; PFS, pre-filled syringe; PGA, Physician Global Assessment; RRAS, re-randomized analysis set; SAE, serious adverse event.


Important Safety Information

OTULFI (ustekinumab-aauz) is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in OTULFI (ustekinumab-aauz).

Infections
Ustekinumab products may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ustekinumab products.
Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following:

  • Plaque psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, urinary tract infections
  • Psoriatic arthritis: cholecystitis
  • Crohn’s disease: anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, Listeria meningitis
  • Ulcerative colitis: gastroenteritis, ophthalmic herpes zoster, pneumonia, listeriosis

Avoid initiating treatment with OTULFI (ustekinumab-aauz) in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of OTULFI (ustekinumab-aauz) in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with OTULFI (ustekinumab-aauz).

Discontinue OTULFI (ustekinumab-aauz) for serious or clinically significant infections until the infection resolves or is adequately treated.

Theoretical Risk for Vulnerability to Particular Infections
Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), Salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients.

It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with ustekinumab products may be susceptible to these types of infections. Consider appropriate diagnostic testing (e.g., tissue culture, stool culture, as dictated by clinical circumstances).

Pre-Treatment Evaluation of Tuberculosis (TB)
Evaluate patients for TB prior to initiating treatment with OTULFI (ustekinumab-aauz).
Avoid administering OTULFI (ustekinumab-aauz) to patients with active TB infection. Initiate treatment of latent TB before administering OTULFI (ustekinumab-aauz). Consider anti-TB therapy prior to initiation of OTULFI (ustekinumab-aauz) in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Closely monitor patients receiving OTULFI (ustekinumab-aauz) for signs and symptoms of active TB during and after treatment.
 
Malignancies
Ustekinumab products are immunosuppressants and may increase the risk of malignancy. Malignancies were reported among subjects who received ustekinumab in clinical trials. In rodent models, inhibition of IL-12/IL-23p40 increased the risk of malignancy.
The safety of ustekinumab products has not been evaluated in patients who have a history of malignancy or who have a known malignancy.
There have been reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving ustekinumab products who had pre-existing risk factors for developing non-melanoma skin cancer (NMSC). Monitor all patients receiving OTULFI (ustekinumab-aauz) for the appearance of NMSC. Closely follow patients >60 years of age, those with a medical history of prolonged immunosuppressant therapy, and those with a history PUVA treatment.
 
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with ustekinumab products. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue OTULFI (ustekinumab-aauz).
 
Posterior Reversible Encephalopathy Syndrome (PRES)
Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in postmarketing experience in patients with psoriasis, psoriatic arthritis and Crohn’s disease. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after initiating ustekinumab products. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab.
Monitor all patients treated with OTULFI (ustekinumab-aauz) for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue OTULFI (ustekinumab-aauz).
 
Immunizations
Prior to initiating therapy with OTULFI (ustekinumab-aauz), patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with OTULFI (ustekinumab-aauz) should not receive live vaccines. Avoid administering BCG vaccines during treatment with OTULFI (ustekinumab-aauz), or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving OTULFI (ustekinumab-aauz) because of the potential risk for shedding from the household contact and transmission to patient.
Non-live vaccinations received during a course of OTULFI (ustekinumab-aauz) may not elicit an immune response sufficient to prevent disease.
 
Noninfectious Pneumonia
Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab products. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and in certain cases, administration of corticosteroids. If diagnosis is confirmed, discontinue OTULFI (ustekinumab-aauz) and institute appropriate treatment.
 
Most Common Adverse Reactions
The most common adverse reactions (≥3%) seen in patients treated with OTULFI (ustekinumab-aauz) are:

  • Psoriasis: nasopharyngitis, upper respiratory tract infection, headache, fatigue
  • Crohn’s disease, induction: vomiting
  • Crohn’s disease, maintenance: nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, sinusitis
  • Ulcerative colitis, induction: nasopharyngitis
  • Ulcerative colitis, maintenance: nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, nausea

 

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS

OTULFI (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of:

    • Adult patients with: 
      • Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
      • Active psoriatic arthritis
      • Moderately to severely active Crohn’s disease
      • Moderately to severely active ulcerative colitis
    • Pediatric patients ≥6 years of age with:
      • Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
      • Active psoriatic arthritis

    Please see Full Prescribing Information for OTULFI.

    References:

    1. Papp K, Balser S, Nopora K, Rewerski P, Freudensprung B, Trieb M. A randomised, double-blind trial to compare the efficacy, safety, and immunogenicity of the biosimilar ustekinumab FYB202 with reference ustekinumab in patients with moderate-to-severe plaque psoriasis. Adv Ther. 2025;42(5):2135-2149. 
    2. Golhen K, Winskill C, Theiler M, et al. Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. Front Med (Lausanne). 2022;9:944208. 
    3. Data on file. Fresenius Kabi USA, LLC.
       
    Indications

    Adults & children 6 years+ with moderate to severe

    OTULFI (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of adults and pediatric patients ≥6 years of age with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

    Adults & children 6 years+ with active

    OTULFI (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of adults and pediatric patients ≥6 years of age with active psoriatic arthritis.

    Adults with moderately to severely active

    OTULFI (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of adult patients with moderately to severely active Crohn’s disease.

    Adults with moderately to severely active

    OTULFI (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of adult patients with moderately to moderately to severely active ulcerative colitis.